SecBot SecBot

EDSA

Edesa Biotech, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001540159 Biotech & Drug Discovery
$2.63 +0.04 (+1.54%)
Oct 27 4:00 PM ET · prev $2.59
Market cap
$37.4M
Nano cap
Median target
$19.00
+622% · range $9.00–21.00
1 year
+21.8%
from $2.16 · Oct 28
30 days
−27.9%
from $3.65
52-week range
$0.8000–18.28
−86% from high · low Feb 20
Avg volume 20D
44.6K
shares / day
Short interest
161.3K
≈1.2% of shares · −20.8%
Days to cover
3.5
at average volume
Insider net
+$233.1K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/4
Strongest NEUTRAL Edesa Biotech announced FDA clearance of its IND application for EB06, a monoclonal antibody targeting…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $233.1K at an average $2.69. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.400 → −$0.583 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersCOVERING

    Short interest −20.8% to 161.3K shares. 3.5 days to cover, ≈1.2% of shares.

  • TrendDOWNTREND

    33% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCTRIM72,465$589.1K
UBS Group AGDOUBLED6,763$55.0K
GEODE CAPITAL MANAGEMENT, LLCADD77,054$403.0K
STATE STREET CORPDOUBLED37,979$198.6K
UBS Group AGADD2,343$12.3K
UBS Group AGTRIM1,362$1.9K
VANGUARD GROUP INCDOUBLED45,543$111.1K
GEODE CAPITAL MANAGEMENT, LLCADD45,234$110.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Nov 2025
12-month targets · 3 analysts

Price is below the lowest target. Median implies +622%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Nov 3, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 13, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$233.1K
bought · 2 insiders
$0
sold · 0 insiders
−2.3%
vs their $2.69 cost
DateInsiderTypeValue
Oct 5, 2026
Nijhawan Pardeep
Chief Executive Officer
AWARD6,893 sh
Sep 1, 2026
Nijhawan Pardeep
Chief Executive Officer
AWARD5,714 sh
Aug 3, 2026
Nijhawan Pardeep
Chief Executive Officer
AWARD5,324 sh
Jul 2, 2026
Nijhawan Pardeep
Chief Executive Officer
AWARD3,378 sh
Jun 16, 2026
Nijhawan Pardeep
Chief Executive Officer
AWARD$800.0K
Jun 1, 2026
Nijhawan Pardeep
Chief Executive Officer
AWARD1,671 sh
May 27, 2026
Liu Da David
Director
AWARD19,000 sh
May 27, 2026
Chypyha Joan
Director
AWARD19,000 sh

Earnings setup

Estimates
−$0.58
EPS estimate, this quarter
−46%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.58-$0.60–-$0.57-34.1%$0.00
Next Q———$0.00
Current FY-$1.99-$1.99–-$1.98-19.7%$0.00
Next FY-$2.07-$2.46–-$1.46-2.8%$0.00

Short side

FINRA· Oct 15, 2026
161,309
shares short
-20.8%
vs prior settlement
3.5
days to cover
≈1.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Edesa Biotech filed an 8-K on October 23, 2026, reporting that its Board approved substantial increases in the annual…
8-K — Impact 2/10
Oct 15, 2026 SEC
Edesa Biotech announced FDA clearance of its IND application for EB06, a monoclonal antibody targeting CXCL10…
8-K — Impact 4/10
Oct 15, 2026 Press
Edesa Biotech announced FDA clearance of its IND for EB06, a monoclonal antibody targeting CXCL10, enabling expansion…
Impact 4/10
Oct 15, 2026 FDA
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
Enables expansion of ongoing vitiligo clinical study to U.S. investigational sitesTopline data antic
Oct 5, 2026 Insider
Nijhawan Pardeep was granted 6,893 shares
Chief Executive Officer
Sep 1, 2026 Insider
Nijhawan Pardeep was granted 5,714 shares
Chief Executive Officer
Aug 19, 2026 Press
Edesa Biotech priced a $25M underwritten public offering of common shares and warrants at $5.50 per unit, with an…
Impact 7/10
Aug 3, 2026 Insider
Nijhawan Pardeep was granted 5,324 shares
Chief Executive Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
FDA
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
Enables expansion of ongoing vitiligo clinical study to U.S. investigational sitesTopline data anticipated Q4 2027 TORONTO, Oct. 15, 2026 (GLOBE...
Sep 30, 2026
Clinical Trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
Phase 3 · TERMINATED
Aug 19, 2026
Activist
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company…
Aug 19, 2026
Regulatory
Edesa Biotech Announces Proposed Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company…
Aug 6, 2026
Earnings date
EDSA Q3 2026 Earnings Scheduled — 2026-08-06

SecBot reports

11 filings · 4 press releases · 2 bullish · 1 bearish · 8 neutral
All EDSA filing & press-release reports (15)